Project Grant P01CA296429
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, EE. UU.
Similar Awards
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer". The award began on March 1, 2025 and is set to conclude on February 28, 2030. The research aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation and progression,...
- The University of Southern California received a $426,828 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on August 15, 2025. The grant supports research to develop DNA methylation markers for early detection and monitoring of tumor burden in bladder cancer. The research aims to identify non-invasive biomarkers in urine samples that can detect bladder cancer recurrence at an earlier stage and monitor tumor response during treatment. This...
- The National Cancer Institute, a component of the National Institutes of Health, awarded a $684,877 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Icahn School of Medicine at Mount Sinai. The grant will support a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer to identify novel therapeutic targets for patients resistant to the standard first-line treatment, Bacillus Calmette-Guerin (BCG). The research project aims to generate...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $168,000.00 in funding to Albert Einstein College of Medicine to conduct research on risk factors and prediction modeling for multiple recurrences of non-muscle invasive bladder cancer (NMIBC). The project aims to: 1) examine associations between demographic, lifestyle, social, tumor, and treatment factors and the risk of first and multiple NMIBC recurrences, and 2) develop...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to investigate the role of EP300 mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Study how EP300 loss-of-function mutations mediate resistance to FGFR inhibitors like erdafitinib using patient-derived bladder cancer models. Identify genomic alterations, especially EP300...
- This $930,500 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports innovative research by the University of Arizona to understand the fundamental biological mechanisms of cancer development, progression, and potential therapeutic interventions. The research focuses on investigating the role of loss of chromosome Y (LOY) in bladder cancer, examining how LOY in both tumor cells and immune cells can promote cancer growth and induce tumor...
- The National Cancer Institute (NCI) awarded a $712,735 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Southern California (USC) on June 1, 2025. This grant will fund a Phase II clinical trial to evaluate the efficacy of a combination therapy using the novel agent SEPHB4-HSA, an EphrinB2 inhibitor, and the PD-1 antibody Pembrolizumab in urothelial carcinoma (bladder cancer) patients whose tumors express EphrinB2 and have low/non-expressing Nectin4...
- This $2,970,010 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by Northwestern University to study the mechanisms by which somatic truncation mutations in the histone methyltransferase KMT2D (also known as MLL4) alter its subcellular localization and drive tumorigenesis in bladder cancer. The key goals are to: 1) define how MLL4 truncation and cytoplasmic relocalization impact its normal functions and...
- This Project Grant award of $1,412,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a biorepository and community development project to characterize aggressive urothelial cancer variants. The University of Washington, as the prime awardee, will conduct this research over a period of approximately 4 years, from September 2024 through August 2028. The project aims to expand understanding of aggressive forms of urothelial (bladder)...